drugset / Trial / NCT03388853

Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.

NCT03388853

Phase 4 Completed 68 enrolled Neutec Ar-Ge San ve Tic A.Ş
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective is to assess efficacy and safety of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet once daily treatment besides standard/usual treatment, as compared with placebo once daily in patients with stable moderate to severe COPD.

Timeline

Start
2018-02-20
Primary completion
2019-12-21
Completion
2019-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxofylline Small molecule 400 mg
Subject N-acetylcysteine Small molecule 1200 mg